Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Tumor analysis of MMR genes in Lynch-like syndrome, Challenges associated with results interpretation

  • Rofes, Paula|||0000-0001-6045-7879
  • Dueñas Cid, Nuria|||0000-0001-6624-3265
  • Del Valle, Jesús|||0000-0003-3607-7045
  • Navarro, Matilde
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Tuset, Noemí
  • Castillo, Carmen
  • González, Sara
  • Brunet, Joan|||0000-0003-1945-3512
  • Capella, Gabriel|||0000-0002-4669-7320
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Pineda, Marta|||0000-0002-5403-5845
Up to 70% of suspected Lynch syndrome patients harboring MMR deficient tumors lack identifiable germline pathogenic variants in MMR genes, being referred to as Lynch-like syndrome (LLS). Previous studies have reported biallelic somatic MMR inactivation in a variable range of LLS-associated tumors. Moreover, translating tumor testing results into patient management remains controversial. Our aim is to assess the challenges associated with the implementation of tumoral MMR gene testing in routine workflows. Methods: Here, we present the clinical characterization of 229 LLS patients. MMR gene testing was performed in 39 available tumors, and results were analyzed using two variant allele frequency (VAF) thresholds (≥5% and ≥10%). Results and Discussion: More biallelic somatic events were identified at VAF ≥ 5% than ≥10% (35.9% vs. 25.6%), although the rate of nonconcordant results regarding immunohistochemical pattern increased (30.8% vs. 20.5%). Interpretation difficulties question the current utility of the identification of MMR somatic hits in the diagnostic algorithm of suspected LS cases.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

SpadaHC, a database to improve the classification of variants in hereditary cancer genes in the Spanish population

  • Moreno-Cabrera, José Marcos|||0000-0001-8570-0345
  • Feliubadaló, Lidia|||0000-0002-1736-0112
  • Pineda, Marta|||0000-0002-5403-5845
  • Prada Dacasa, Patricia|||0000-0003-0689-9072
  • Ramos-Muntada, Mireia|||0000-0002-5531-1442
  • Del Valle, Jesús|||0000-0003-3607-7045
  • Brunet, Joan|||0000-0003-1945-3512
  • Gel, Bernat|||0000-0001-8878-349X
  • Currás-Freixes, M.
  • Calsina Pla Giribert, Bruna|||0000-0002-6922-9415
  • Salazar-Hidalgo, Milton E.
  • Rodríguez-Balada, M.
  • Roig, Bàrbara
  • Fernández-Castillejo, Sara|||0000-0002-8109-9713
  • Durán, Mercedes|||0000-0002-6301-9732
  • Arranz Ledo, Mónica
  • Infante, Mar
  • Castillejo Castillo, Adela|||0000-0002-9581-6285
  • Dámaso, Estela|||0000-0002-9650-7791
  • Soto, José Luis
  • de Miguel, Montserrat
  • Hidalgo Calero, Beatriz
  • Sánchez-Zapardiel, José M.
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Lasa, Adriana|||0000-0001-9957-9646
  • Gisbert-Beamud, Alexandra|||0000-0001-6515-3081
  • López Novo, Anael
  • Ruiz-Ponte, C.
  • Potrony, Miriam|||0000-0003-2766-0765
  • Álvarez Mora, María Isabel|||0000-0003-3788-8915
  • Osorio, Ana|||0000-0001-8124-3984
  • Lorda Sánchez, Isabel
  • Robledo, Mercedes|||0000-0001-6256-5902
  • Cascón, Alberto|||0000-0003-2119-891X
  • Ruiz, Anna|||0000-0001-7314-5962
  • Spataro, Nino|||0000-0002-2127-2238
  • Hernán Sendra, Imma
  • Borràs, Emma
  • Moles-Fernández, Alejandro|||0000-0003-0252-6084
  • Earl, Julie
  • Cadiñanos, J.
  • Sánchez-Heras, Ana Beatriz|||0000-0003-1742-5374
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Capella, Gabriel|||0000-0002-4669-7320
  • Lázaro, C.
Accurate classification of genetic variants is crucial for clinical decision-making in hereditary cancer. In Spain, genetic diagnostic laboratories have traditionally approached this task independently due to the lack of a dedicated resource. Here we present SpadaHC, a web-based database for sharing variants in hereditary cancer genes in the Spanish population. SpadaHC is implemented using a three-tier architecture consisting of a relational database, a web tool and a bioinformatics pipeline. Contributing laboratories can share variant classifications and variants from individuals in Variant Calling Format (VCF) format. The platform supports open and restricted access, flexible dataset submissions, automatic pseudo-anonymization, VCF quality control, variant normalization and liftover between genome builds. Users can flexibly explore and search data, receive automatic discrepancy notifications and access SpadaHC population frequencies based on many criteria. In February 2024, SpadaHC included 18 laboratory members, storing 1.17 million variants from 4306 patients and 16 343 laboratory classifications. In the first analysis of the shared data, we identified 84 genetic variants with clinically relevant discrepancies in their classifications and addressed them through a three-phase resolution strategy. This work highlights the importance of data sharing to promote consistency in variant classifications among laboratories, so patients and family members can benefit from more accurate clinical management.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Detection of germline CNVs from gene panel data, benchmarking the state of the art

  • Munté, Elisabet|||0000-0001-8396-8284
  • Roca, Carla|||0000-0003-1171-0588
  • Del Valle, Jesús|||0000-0003-3607-7045
  • Feliubadaló, Lidia|||0000-0002-1736-0112
  • Pineda, Marta|||0000-0002-5403-5845
  • Gel, Bernat|||0000-0001-8878-349X
  • Castellanos, Elisabeth|||0000-0002-8133-5325
  • Rivera, Bárbara
  • Cordero, David
  • Lázaro, Contxi
  • Moreno-Cabrera, José Marcos|||0000-0001-8570-0345
Germline copy number variants (CNVs) play a significant role in hereditary diseases. However, the accurate detection of CNVs from targeted next-generation sequencing (NGS) gene panel data remains a challenging task. Several tools for calling CNVs within this context have been published to date, but the available benchmarks suffer from limitations, including testing on simulated data, testing on small datasets, and testing a small subset of published tools. In this work, we conducted a comprehensive benchmarking of 12 tools (Atlas-CNV, ClearCNV, ClinCNV, CNVkit, Cobalt, CODEX2, CoNVaDING, DECoN, ExomeDepth, GATK-gCNV, panelcn.MOPS, VisCap) on four validated gene panel datasets using their default parameters. We also assessed the impact of modifying 107 tool parameters and identified 13 parameter values that we suggest using to improve the tool F1 score. A total of 66 tool pair combinations were also evaluated to produce better meta-callers. Furthermore, we developed CNVbenchmarker2, a framework to help users perform their own evaluations. Our results indicated that in terms of F1 score, ClinCNV and GATK-gCNV were the best CNV callers. Regarding sensitivity, GATK-gCNV also exhibited particularly high performance. The results presented here provide an evaluation of the current state of the art in germline CNV detection from gene panel data and can be used as a reference resource when using any of the tools.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Constitutional epimutations in LTBP4, a component of the TGF-β signaling, and in BRCA1, as potential drivers of early-onset colorectal cancer

  • Terradas, Mariona|||0000-0001-7813-1172
  • Mur, Pilar
  • Bousquets-Muñoz, Pablo
  • Puente, Xose S.|||0000-0001-9525-1483
  • Nielsen, Maartje|||0000-0002-5351-1870
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Valle, Laura|||0000-0003-0371-0844
  • Morón-Duran, Francisco D.
  • Mengod, Pol
  • Löffler, Chiara M.L.
  • Helderman, Noah C.
  • Terlouw, Diantha
  • Sanjuán, Xavier
  • Viana-Errasti, Julen
  • Capellá, Gabriel
  • van Wezel, Tom
  • Kather, Jakob Nikolas
Background: Constitutional primary monoallelic promoter methylation of hereditary cancer genes, although rare, may explain early-onset cancers without family history. Also, promoter methylation of a hereditary cancer gene secondary to a genetic alteration in a methylation regulatory region can cause a hereditary cancer syndrome. This study investigates constitutional promoter methylation as mechanism of inactivation of cancer predisposition genes in genetically unsolved familial and/or early-onset colorectal cancer (CRC) patients. Results: Bisulfite-treated peripheral blood DNA from 46 early-onset/familial CRC patients was analyzed using the Illumina Infinium MethylationEPIC BeadChip. One early-onset CRC patient exhibited constitutional, likely monoallelic, methylation of CpG island 102 in LTBP4, a gene involved in TGF-β signaling. Somatic methylation of this CpG island is common in CRC, and correlates with LTBP4 downregulation. LTBP4 double knockout mice develop colorectal adenomas and carcinomas, supporting the role of this gene in CRC predisposition. No additional cases with constitutional LTBP4 CpG island 102 methylation or enrichment of deleterious LTBP4 variants in CRC patients compared to controls were found. Another early-onset CRC patient exhibited mosaic BRCA1 promoter methylation, typically associated with increased breast and ovarian cancer risk. No somatic second hit in BRCA1 was detected in the patient's tumor, and homologous recombination deficiency-associated features were inconclusive. Conclusions: Our findings suggest that constitutional methylation of LTBP4 CpG island 102 may be associated with increased CRC risk. Identification of additional cases is needed to confirm the existence of a novel CRC predisposition syndrome driven by epigenetic inactivation of LTBP4, potentially also linked to other clinical phenotypes associated with LTBP4 deficiency, such as pulmonary emphysema. Whether constitutional BRCA1 methylation contributes to CRC risk remains to be determined.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Comparative Analysis of Somatic and Germline Polymerase Proofreading Deficiencies in Cancer: Molecular and Clinical Implications

  • Viana-Errasti, Julen
  • Marín, Raúl
  • García-Mulero, Sandra
  • Pons, Tirso
  • Terradas, Mariona
  • Capellá, Gabriel
  • Moreno, Victor
  • Mur, Pilar
  • Valle, Laura
Supplementary Material https://www.sciencedirect.com/science/article/pii/S0893395225001401?via%3Dihub#cebib0010:~:text=This,publication, Polymerases ε and δ maintain genome integrity through exonuclease proofreading. Germline and somatic pathogenic variants (PVs) in the exonuclease domain (ED) of POLE and POLD1 impair proofreading, causing hypermutated tumors. Despite shared mutational features that make these tumors highly immunogenic, molecular and clinical distinctions between POLE and POLD1 mutations and between somatic and germline variants remain incompletely understood. We compared the molecular and clinical characteristics of POLE and POLD1 ED PVs (n = 31), assessing their location, pathogenicity, clinical phenotypes, mismatch repair (MMR) status, tumor mutational burden, and signatures. We analyzed 360 proofreading-deficient tumors (source: The Cancer Genome Atlas [TCGA] and Catalogue Of Somatic Mutations In Cancer [COSMIC]) and 70 families (249 individuals) with polymerase proofreading-associated polyposis. All germline and somatic PVs had high AlphaMissense scores (0.87-1) and clustered within or near Exo motifs. Recurrent, nonfounder germline PVs, POLE L424V and POLD1 S478N, showed low/modest REVEL scores. Somatic variants occurred mainly in endometrial cancers (75% of proofreading-deficient TCGA cancers), whereas colorectal cancer predominated in polymerase proofreading-associated polyposis (56% of carriers). Cancer risks and tumor spectra differed between POLE and POLD1 PV carriers. Aggressive hereditary phenotypes were linked to either specific POLE PVs (eg, S297F, V411L, P436R, M444K, A456P, and S461T) or the co-occurrence of germline ED PVs with germline MMR gene PVs. Distinct hypermutator profiles were confirmed for polymerase ε and polymerase δ proofreading deficiencies via unique mutational signatures (Polymerase ε: SBS10a/b, SBS28; Polymerase δ: SBS10c/d). Tumors with combined proofreading and MMR deficiencies had significantly higher tumor mutational burden and a shift in the associated mutational spectra. Unlike POLE, POLD1 ED PVs exhibited haplosufficiency, typically requiring a somatic second hit (eg, loss of heterozygosity) or MMR deficiency to drive hypermutation. In conclusion, differences between POLE and POLD1 and between somatic and germline mutations influence clinical presentation, mutagenic potential, and reliance on cooperating defects in tumorigenesis. These insights advance the understanding of proofreading-deficient cancers, with implications for diagnostics, genetic counseling, and precision oncology., This study was funded by the Spanish Ministry of Science and Innovation (Agencia Estatal de Investigación), cofunded by FEDER funds a way to build Europe (PID2024-162582OB-I00; PID2020-112595RB-I00, AEI/10.13039/501100011033 and “Contrato predoctoral para la formación de doctores” [J.V.-E.]); Instituto de Salud Carlos III [CIBERONC CB16/12/00234; PMP22/00064, also funded by NextGenerationEU (MRR)/PRTR]; Government of Catalonia [AGAUR 2021SGR01112; CERCA Program for institutional support (IDIBELL)]. None of the study sponsors had any involvement in the study design, collection, analysis and interpretation of data, writing of the report and decision to submit the article for publication., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Role of POLE and POLD1 in familial cancer

  • Mur, Pilar
  • García-Mulero, Sandra
  • Vidal, August
  • Balmaña Gelpí, Judith
  • Pineda, Marta
  • del Valle, Jesús
  • Magraner-Pardo, Lorena
Domini de l'exonucleasa; Càncer colorectal hereditari; Fenotip ultramutat, Dominio exonucleasa; Cáncer colorrectal hereditario; Fenotipo ultramutado, Exonuclease domain; Hereditary colorectal cancer; Ultramutated phenotype, Purpose Germline pathogenic variants in the exonuclease domain (ED) of polymerases POLE and POLD1 predispose to adenomatous polyps, colorectal cancer (CRC), endometrial tumors, and other malignancies, and exhibit increased mutation rate and highly specific associated mutational signatures. The tumor spectrum and prevalence of POLE and POLD1 variants in hereditary cancer are evaluated in this study. Methods POLE and POLD1 were sequenced in 2813 unrelated probands referred for genetic counseling (2309 hereditary cancer patients subjected to a multigene panel, and 504 patients selected based on phenotypic characteristics). Cosegregation and case–control studies, yeast-based functional assays, and tumor mutational analyses were performed for variant interpretation. Results Twelve ED missense variants, 6 loss-of-function, and 23 outside-ED predicted-deleterious missense variants, all with population allele frequencies <1%, were identified. One ED variant (POLE p.Met294Arg) was classified as likely pathogenic, four as likely benign, and seven as variants of unknown significance. The most commonly associated tumor types were colorectal, endometrial and ovarian cancers. Loss-of-function and outside-ED variants are likely not pathogenic for this syndrome. Conclusions Polymerase proofreading–associated syndrome constitutes 0.1–0.4% of familial cancer cases, reaching 0.3–0.7% when only CRC and polyposis are considered. ED variant interpretation is challenging and should include multiple pieces of evidence., We thank Gemma Aiza, Mireia Menéndez, Sara González, and Xavier Muñoz for support, and Biobanc HUB-ICO-IDIBELL, integrated in the Spanish Platform Biobanks Network and funded by Instituto de Salud Carlos III (PT17/0015/0024) and Xarxa Bancs de Tumors de Catalunya sponsored by Pla Director d’Oncologia de Catalunya. This work was funded by the Spanish Ministry of Science and Innovation, cofunded by FEDER funds (SAF2016-80888-R, SAF2015-68016-R, Severo Ochoa SVP-2014-068895 contract [L.M.-P.]); Instituto de Salud Carlos III (PI16/00563, PI16/00588, PI14/00613, PI19/00553, CIBERONC CB16/12/00234, CIBERESP, Sara Borrell contract [P.M.]); Government of Catalonia [AGAUR 2017SGR1282, CERCA Program]; and Fundación Olga Torres. This study was facilitated by COST Action CA17118, supported by COST (European Cooperation in Science and Technology).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Role of POLE and POLD1 in familial cancer

  • Mur, Pilar
  • García-Mulero, Sandra|||0000-0003-4931-1267
  • Del Valle, Jesús|||0000-0003-3607-7045
  • Magraner-Pardo, Lorena
  • Vidal, August|||0000-0001-5727-2099
  • Pineda, Marta|||0000-0002-5403-5845
  • Cinnirella, Giacomo
  • Martín-Ramos, Edgar
  • Pons, Tirso|||0000-0002-7616-7750
  • López-Doriga, Adriana
  • Belhadj, Sami|||0000-0002-0528-9187
  • Feliubadaló, Lidia|||0000-0002-1736-0112
  • Munoz-Torres, Pau M.|||0000-0002-0168-3224
  • Navarro, Matilde
  • Grau, Elia
  • Darder, Esther
  • Llort, Gemma|||0000-0001-9987-7862
  • Sanz, Judit
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Brunet, Joan|||0000-0003-1945-3512
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Piulats, Josep M.|||0000-0002-3606-1724
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Sanz-Pamplona, Rebeca
  • Aligué, Rosa
  • Capella, Gabriel|||0000-0002-4669-7320
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Valle, Laura|||0000-0003-0371-0844
Germline pathogenic variants in the exonuclease domain (ED) of polymerases POLE and POLD1 predispose to adenomatous polyps, colorectal cancer (CRC), endometrial tumors, and other malignancies, and exhibit increased mutation rate and highly specific associated mutational signatures. The tumor spectrum and prevalence of POLE and POLD1 variants in hereditary cancer are evaluated in this study. POLE and POLD1 were sequenced in 2813 unrelated probands referred for genetic counseling (2309 hereditary cancer patients subjected to a multigene panel, and 504 patients selected based on phenotypic characteristics). Cosegregation and case-control studies, yeast-based functional assays, and tumor mutational analyses were performed for variant interpretation. Twelve ED missense variants, 6 loss-of-function, and 23 outside-ED predicted-deleterious missense variants, all with population allele frequencies <1%, were identified. One ED variant (POLE p.Met294Arg) was classified as likely pathogenic, four as likely benign, and seven as variants of unknown significance. The most commonly associated tumor types were colorectal, endometrial and ovarian cancers. Loss-of-function and outside-ED variants are likely not pathogenic for this syndrome. Polymerase proofreading-associated syndrome constitutes 0.1-0.4% of familial cancer cases, reaching 0.3-0.7% when only CRC and polyposis are considered. ED variant interpretation is challenging and should include multiple pieces of evidence.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Role of POLE and POLD1 in familial cancer

  • Mur, Pilar
  • García-Mulero, Sandra
  • Vidal, August
  • Balmaña Gelpí, Judith
  • Pineda, Marta
  • del Valle, Jesús
  • Magraner-Pardo, Lorena
Domini de l'exonucleasa; Càncer colorectal hereditari; Fenotip ultramutat, Dominio exonucleasa; Cáncer colorrectal hereditario; Fenotipo ultramutado, Exonuclease domain; Hereditary colorectal cancer; Ultramutated phenotype, Purpose Germline pathogenic variants in the exonuclease domain (ED) of polymerases POLE and POLD1 predispose to adenomatous polyps, colorectal cancer (CRC), endometrial tumors, and other malignancies, and exhibit increased mutation rate and highly specific associated mutational signatures. The tumor spectrum and prevalence of POLE and POLD1 variants in hereditary cancer are evaluated in this study. Methods POLE and POLD1 were sequenced in 2813 unrelated probands referred for genetic counseling (2309 hereditary cancer patients subjected to a multigene panel, and 504 patients selected based on phenotypic characteristics). Cosegregation and case–control studies, yeast-based functional assays, and tumor mutational analyses were performed for variant interpretation. Results Twelve ED missense variants, 6 loss-of-function, and 23 outside-ED predicted-deleterious missense variants, all with population allele frequencies <1%, were identified. One ED variant (POLE p.Met294Arg) was classified as likely pathogenic, four as likely benign, and seven as variants of unknown significance. The most commonly associated tumor types were colorectal, endometrial and ovarian cancers. Loss-of-function and outside-ED variants are likely not pathogenic for this syndrome. Conclusions Polymerase proofreading–associated syndrome constitutes 0.1–0.4% of familial cancer cases, reaching 0.3–0.7% when only CRC and polyposis are considered. ED variant interpretation is challenging and should include multiple pieces of evidence., We thank Gemma Aiza, Mireia Menéndez, Sara González, and Xavier Muñoz for support, and Biobanc HUB-ICO-IDIBELL, integrated in the Spanish Platform Biobanks Network and funded by Instituto de Salud Carlos III (PT17/0015/0024) and Xarxa Bancs de Tumors de Catalunya sponsored by Pla Director d’Oncologia de Catalunya. This work was funded by the Spanish Ministry of Science and Innovation, cofunded by FEDER funds (SAF2016-80888-R, SAF2015-68016-R, Severo Ochoa SVP-2014-068895 contract [L.M.-P.]); Instituto de Salud Carlos III (PI16/00563, PI16/00588, PI14/00613, PI19/00553, CIBERONC CB16/12/00234, CIBERESP, Sara Borrell contract [P.M.]); Government of Catalonia [AGAUR 2017SGR1282, CERCA Program]; and Fundación Olga Torres. This study was facilitated by COST Action CA17118, supported by COST (European Cooperation in Science and Technology).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Altered chromatin landscape and 3D interactions associated with primary constitutional MLH1 epimutations

  • Climent-Cantó, Paula
  • Subirana Granés, Marc
  • Ramos-Rodríguez, Mireia
  • Dámaso, Estela
  • Marín, Fátima
  • Vara, Covadonga
  • Pérez-González, Beatriz
  • Raurell, Helena
  • Munté, Elisabeth
  • Soto, José Luis
  • Alonso Sánchez, Ángel Miguel
  • Shin, GiWon
  • Ji, Hanlee
  • Hitchins, Megan
  • Capellá, Gabriel
  • Pasquali, Lorenzo
  • Pineda, Marta
Background: Lynch syndrome (LS), characterised by an increased risk for cancer, is mainly caused by germline pathogenic variants affecting a mismatch repair gene (MLH1, MSH2, MSH6, PMS2). Occasionally, LS may be caused by constitutional MLH1 epimutation (CME) characterised by soma-wide methylation of one allele of the MLH1 promoter. Most of these are "primary" epimutations, arising de novo without any apparent underlying cis-genetic cause, and are reversible between generations. We aimed to characterise genetic and gene regulatory changes associated with primary CME to elucidate possible underlying molecular mechanisms. Methods: Four carriers of a primary CME and three non-methylated relatives carrying the same genetic haplotype were included. Genetic alterations were sought using linked-read WGS in blood DNA. Transcriptome (RNA-seq), chromatin landscape (ATAC-seq, H3K27ac CUT&Tag) and 3D chromatin interactions (UMI-4C) were studied in lymphoblastoid cell lines. The MLH1 promoter SNP (c.-93G > A, rs1800734) was used as a reporter in heterozygotes to assess allele-specific chromatin conformation states. Results: MLH1 epimutant alleles presented a closed chromatin conformation and decreased levels of H3K27ac, as compared to the unmethylated allele. Moreover, the epimutant MLH1 promoter exhibited differential 3D chromatin contacts, including lost and gained interactions with distal regulatory elements. Of note, rare genetic alterations potentially affecting transcription factor binding sites were found in the promoter-contacting region of CME carriers. Conclusions: Primary CMEs present allele-specific differential interaction patterns with neighbouring genes and regulatory elements. The role of the identified cis-regulatory regions in the molecular mechanism underlying the origin and maintenance of CME requires further investigation., This study was supported by the National Institute of Health/National Cancer Institute (R01CA218342), the Spanish Ministry of Science and Innovation, which is part of Agencia Estatal de Investigación (AEI), through the Retos Investigación grants (SAF2015-68016-R, PID2019-111254RB-I00, PID2020-117099RB-I00, PID2023-151585OB-I00, and SAF2017-86242-R), CIBERONC (CB16/12/00234), and the Secretariat for Universities and Research of the Department of Business and Knowledge of the Generalitat de Catalunya grant to support the activities of research groups (2021 SGR 01112). M.R.-R. is supported by the IMPULSO Talento Joven grant from DiabetesCERO and the EFSD/Lilly Young Investigator Award.